Syros Pharmaceuticals

128 articles with Syros Pharmaceuticals

• Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

  3/2/2023

  Syros Pharmaceuticals today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

• Syros to Participate in Upcoming Investor Conferences in March - February 28, 2023

  2/28/2023

  Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March.

• Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

  2/23/2023

  Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

• Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 09, 2023

  2/9/2023

  Syros Pharmaceuticals announced the grant of restricted stock unit awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.

• Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

  1/26/2023

  Syros Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS).

• Syros Announces Clinical Updates and 2023 Strategic Priorities

  1/9/2023

  Syros Pharmaceuticals today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

• Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 23, 2022

  12/23/2022

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.

• Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

  12/12/2022

  Syros Pharmaceuticals today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy.

• Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

  12/10/2022

  Syros Pharmaceuticals announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia and RARA gene overexpression.

• Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

  12/5/2022

  Syros Pharmaceuticals today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).

• Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

  11/22/2022

  Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

• Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/14/2022

  Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

• Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

  11/7/2022

  Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.

• Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022

  11/4/2022

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 22,610 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

• Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

  11/3/2022

  Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA.

• Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2022

  10/5/2022

  Syros Pharmaceuticals announced the grant of a restricted stock unit award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros.

• Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

  9/16/2022

  Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million.

• Syros and Tyme Technologies Announce Stockholder Approval of Merger

  9/15/2022

  Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022.

• Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

  9/13/2022

  Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer.

• Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Syros Pharmaceuticals announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.